Oestrogen receptor: A stable phenotype in breast cancer

British Journal of Cancer

Volumn 73, Issue 1, 1996, Pages 5-12

  Robertson, J F R ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Oestrogen receptor; Stable phenotype

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; TAMOXIFEN;

BREAST CANCER; CANCER HORMONE THERAPY; FEMALE; HUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

EID: 0030028024     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.2     Document Type: Review

References (115)

1. ALLEGRA JC, BARLOCK A, HUFF KK AND LIPPMAN ME. (1980). Changes in multiple or sequential oestrogen receptor determinations in breast cancer. Cancer, 45, 792-794.
2. ANDERSON EDC, FORREST APM, LEVACK PA, CHETTY U AND HAWKINS RA. (1989). Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer. Br. J. Cancer, 60, 223-226.
3. BISHOP HM. (1982). Oestrogen receptors in human breast cancer. DM Thesis, University of Nottingham.
4. BOJAR, H. (1986). Quality control requirements in estrogen receptor determination. Cancer Res., 46, 4249(s)-4250(s).
5. BRENNER SE, CLARK, GM AND MCGUIRE, WL. (1988). Review: steroid receptors, cellular kinetics and lymph nodes status as prognostic factors in breast cancer. Am. J. Med. Sci., 296, 59-66.
6. BROOKS SC, SAUNDERS DE, SINGHAKOWINTA A AND VAITKE-VICIUS VK. (1980). Relation of tumour content of estrogen and progesterone receptors with response of patient to endocrine therapy. Cancer, 46, 2775-2778.
7. BRUNNER N, BOULAY V, FOJO A, FRETER CE, LIPPMAN ME AND CLARKE R. (1993a). Acquisition of hormone independent growth in MCF-7 cells is accompanied by increased expression of estrogen regulated genes but without detectable DNA amplifications. Cancer Res., 53, 283-290.
8. BRUNNER N, FRANDSEN TL, HOLST-HANSEN C, BEI M, THOMPSON EW, WAKELING AE, LIPPMAN ME AND CLARKE R. (1993b). MCF-7/LCC2 : a 4-hydroxytamoxifen resistant breast cancer variant which retains sensitivity to the steroid antiestrogen ICI 182,780. Cancer Res., 53, 3229-3232.
9. BUR ME, ZIMAROWSKI MJ, SCHIFF SJ, BAKER S AND LEW R. (1992). Estrogen receptor immunocytochemistry in carcinoma in situ of the breast. Cancer, 69, 1174-1181.
10. BUZDAR AV, POWELL KC AND BLUMENSCHEIN GR. (1982). Aminoglutethamide after Tamoxifen in advanced breast cancer: MD Anderson Hospital experience. Cancer Res., 42, 3448s-3450s.
11. CAMPBELL FC, BLAMEY RW, ELSTON CW, MORRIS AH, NICHOLSON RI, GRIFFITHS K AND HAYBITTLE JL. (1981). Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet, 2, 1317-1319.
12. CLARKE GM AND MCGUIRE WL. (1988). Steroid receptors and other prognostic factors in primary breast cancer. Semin. Oncol. 15, (no. 2 suppl). 1, 20-25.
13. CLARKE RB, LAIDLAW IJ, JONES LJ, HOWELL A AND ANDERSON E. (1993). Effect of Tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Br. J. Cancer, 67, 606-611.
14. CLARKE R, SKAAR T, BAUMANN IC, LEONESSA F, JAMES M, LIPPMAN J, THOMPSON EW, FRETER C AND BRUNNER N. (1994). Hormonal carcinogenesis in breast cancer: cellular and molecular studies of malignant progression. Breast Cancer Res. Treat., 31, 237-248.
15. COOKE T, GEORGE WD, SHIELD R, MAYNARD PV AND GRIFFITHS K. (1979). Oestrogen receptors and prognosis in early breast cancer. Lancet, 1, 995-997.
16. COOMBES RC, POWLES TJ, BERGER V, WILSON P, MCCLELLAND RA, GAZET JC, TROTT PA AND FORD HT. (1987). Prediction of endocrine response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirate. Lancet, 2, 701-703.
17. CROTON R, COOKE T, HOLT S, GEORGE WD, NICHOLSON RI AND GRIFFITHS K. (1981). Oestrogen receptors and survival in early breast cancer. Br. Med. J., 283, 1289-1291.
18. DALY RJ AND DARBRE PD. (1990). Cellular and molecular events in loss of eslrogen sensitivity in ZR-75-1 and T47D human breast cancer cells. Cancer Res., 50, 5868-5875.
19. DAVIS BW, ZAVA DT, LOCHER GW, GOLDHIRSCH A AND HARTMANN WH. (1984). Receptor heterogeneity of human breast cancer as measured by multiple intratumoral assays of estrogen and progesterone receptor. Eur. J. Cancer Clin. Oncol., 20, 375-382.
20. DEFRIEND DJ, HOWELL A, NICHOLSON RI, ANDERSON E, DOWSETT M, MANSEL RE, BLAMEY RW, BUNDRED NJ, ROBERTSON JFR, SAUNDERS C, BAUM M, WALTON P, SUTCLIFFE F AND WAKELING A. (1994). Investigation of a new pure anti-estrogen (ICI 182,780) in women with primary breast cancer. Cancer Res., 54, 408-414.
21. ENCARNACION CA, CIOCCA DR, MCGUIRE WL, CLARK GM, FUGUA SAW AND OSBORNE CK. (1993). Measurement of steroid hormone receptors in breast cancer patients on Tamoxifen. Breast Cancer Res. Treat., 26, 237-246.
22. EUSELI V, CERASOLI PT, GUIDELLI-GUIDI S, GRILLI S, BUSSOLATI G AND AZZOPARDI JG. (1981). A two stage immunocytochemical method for oestrogen receptor analysis: correlation with morphologic parameters of breast carcinomas. Tumori, 67, 315-323.
23. EWING TE, MURPHY LJ, NG M-L, PANG GYN, LEE CSL, WATTS CKJW AND SUTHERLAND RL. (1989). Regulation of epidermal growth factor receptor by progestins and glucocorticoids in human breast cancer cell lines. Int. J. Cancer, 44, 744-752.
24. FABIAN C, STERNSON L, EL-SERAFI M, CAIN L AND HEARNE E. (1981). Clinical pharmacology of Tamoxifen in patients with breast cancer: correlation with clinical data. Cancer, 48, 876-882.
25. FUQUA SA, FITZGERALD SD, CHARMNESS GC, TANDON AK, MCDONNELL DP, NAWAZ Z, O'MALLEY BW AND MCGUIRE WL. (1991). Variant human breast tumour estrogen receptor with constitutive transcriptional activity. Cancer Res., 51, 105-109.
26. GASKELL DJ, HAWKINS RA, SANGSTER K, CHETTY U AND FORREST APM. (1989). Relation between immunocytochemical estimation of oestrogen receptor in elderly patients with primary breast cancer and response to tamoxifen. Lancet, 1, 1044-1046.
27. GIRI DD, DUNDAS SAC AND NOTTINGHAM JF AND UNDERWOOD JCE. (1989). Oestrogen receptors in benign epithelial lesions and intraduct carcinomas of the breast: an immunohistological study. Histopathology, 15, 575-584.
28. GOTTARDIS MM AND JORDAN VC. (1988). Development of Tamoxifen-stimulated growth of MCF-7 tumours in athymic mice after long-term anti-estrogen administration. Cancer Res., 48, 5183-5187.
29. GOTTARDIS MM, JIANG S-Y, JENG M-H AND JORDAN VC. (1989). Inhibition of Tamoxifen-stimulated growth of an MCF-7 tumour variant in athymic mice by novel steroidal anti-estrogens. Cancer Res., 49, 4090-4093.
30. GREEN GL AND JENSEN EV. (1992). Monoclonal antibodies as probes for estrogen receptor detection and characteristics. J. Steroid Binchem., 16, 353-359.
31. HAHNEL R, WOODINGS T AND VIVIAN AB. (1979). Prognostic value of oestrogen receptors in primary breast cancer. Cancer, 44, 671-675.
32. HAHNEL R AND TWADDLE E. (1985). The relationship between estrogen receptors in primary and secondary breast carcinomas and in sequential primary breast carcinomas. Breast Cancer Res. Treat., 5, 155-163.
33. HARLAND RNL, BARNES DM, HOWELL A, RIBEIRO G, TAYLOR J AND SELLWOOD RA. (1983). Variation in receptor status in cancer of the breast. Br. J. Cancer, 47, 511-515.
34. HARVEY HA, LIPTON A, WHITE DS, SANTEN RJ, BORCHER AE, SHAFIK AS AND DIXON RJ. (1982). Cross-over comparison of Tamoxifen and Aminoglutethamide in advanced breast cancer. Cancer Res., 42, 3451s-3453s.
35. HAWKINS RA, HILL A AND FREEDMAN B. (1975). A simple method for the determination of estrogen receptor concentrations in breast tumours and other tumours. Clin. Chim. Acta., 64, 203-210.
36. HAWKINS RA, HILL A, FREEDMAN B, GORE SM, ROBERT MM AND FORREST APM. (1977). Reproducibility of measurements of oestrogen receptor concentration in breast cancer. Br. J. Cancer, 36, 355-361.
37. HAWKINS RA, WHITE G, BUNDRED NJ, DIXON JM, MILLER WR, STEWART HJ AND FORREST ADM. (1987a). Prognostic significance of oestrogen and progesterone receptor activities in breast cancer. Br. J. Surg., 74, 1009-1013.
38. HAWKINS RA, SANGSTER K AND TESDALE AL, FERGUSON WA, KRAJEWSKI A, LEVAK PA AND FORREST P. (1987b). Experience with new assays for oestrogen receptors using monoclonal antibodies. Biochem. Soc. Trans., 15, 949-950.
39. HAWKINS RA, SANGSTER K AND TESDALE A. (1988). The cytochemical detection of oestrogen receptors in fine needle aspirates of breast cancer; correlation with biochemical assay and prediction of response to endocrine therapy. Br. J. Cancer, 58, 77-80.
40. HOWELL A, BARNES DM, HARLAND RNL, REDFORD J, BRAMWELL VHC, WILKINSON MJS, SWINDELL R, CROWTHER D AND SELLWOOD RA. (1984). Steroid-hormone receptors in survival after first relapse in breast cancer. Lancet, 1, 588-591.
41. HOWELL A, ANDERSON E, LAIDLAW I, SCHOR A, SCHOR S AND POTTEN C. (1994). Cyclical activity and 'ageing' of the human breast: clues to assessment of risk and strategies for prevention. In: Endocrine Therapy of Breast Cancer VI, Howell A (ed.) pp. 27-46. Springer: Berlin.
42. HOWELL A, DEFRIEND D, ROBERTSON J, BLAMEY R AND WALTON P. (1995). Response to a specific anti-oestrogen (ICI 182,780) in Tamoxifen resistant breast cancer. Lancet, 345, 29-30.
43. JOHNSTON SRD, HAYNES BP, SMITH IE, JARMAN M, SACKS NPM, EBBS SR AND DOWSETT M. (1994). Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet, 2, 1521-1522.
44. JONAT W, MAASS H AND STEGNER HE. (1986). Immunocytochemical measurement of estrogen receptors in breast cancer tissue samples. Cancer Res., 46, 4296s-4298s.
45. JORDAN VC, JACOBSEN HI AND KEENAN EJ. (1986). Determination of estrogen receptor in breast cancer using monoclonal antibody technology. Results of a multi-center study in the United States. Cancer Res., 46, (suppl.) 4237-4240.
46. JORDAN CV. (1994). Drug resistance to antioestrogen therapy. In Endocrine Therapy of Breast Cancer VI, Howell A (ed.) pp. 61-68. Springer: Berlin.
47. KAYE SB, WOODS RL, FOX RM, COATES AS AND TATTERSALL MHN. (1982). Use of Aminoglutethamide as second-line endocrine therapy in metastatic breast cancer. Cancer Res., 42, 3445s-3447s.
48. KIANG DT AND KENNEDY BJ. (1977). Factors affecting estrogen receptors in breast cancer. Cancer, 40, 1571-1576.
49. KING WJ AND GREEN GL. (1984). Monoclonal antibodies localize oestrogen receptor to the nucleus of target cells. Nature, 307, 745-747.
50. KNIGHT WA, LIVINGSTON RB, GREGORY EJ AND MCGUIRE WL. (1977). Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res., 37, 4669-4671.
51. KOHLER G AND MILSTEIN C. (1975). Continuous culture of fused cells secreting antibody of predefined specificity. Nature, 256, 494-497.
52. LECLERQ G, BOJAR H, GOUSSARD J, NICHOLSON RI, PICHON M-F, PIFFANELLI A, POVSETTE A, THORPE S AND LONSDORFER M. (1986). Abbot monoclonal enzyme immunoassay measurement of estrogen receptors in human breast cancer. A European multicenter study. Cancer Res., 46, (suppl.) 4233-4236.
53. LIPPMAN ME AND ALLEGRA JC. (1980). Quantitative estrogen receptor analyses. The response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval. Cancer, 46, 2829-2834.
54. MCCARTY KS JR, SZABO E, FLOWERS JL, COX EB, LEIGHT GS, MILLER L, KAURATH J, SOPER JT, BUDWIT DA, GREASMAN WT, SEIGLER HF AND MCCARTY KS SR. (1986). Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumours. Cancer Res., (suppl.) 46, 4244(s)-4248(s).
55. MCCLELLAND RA, BERGER U, MILLER LS, POWLES TJ AND COOMBES RC. (1986a). Immunocytochemical assay for estrogen receptor in patients with breast cancer: relationship to a biochemical assay and to outcome of therapy. J. Clin. Oncol., 4, 1171-1176.
56. MCCLELLAND RA, BERGER U, MILLER LS, POWLES TJ, JENSEN EV AND COOMBES RC. (1986b). Immunocytochemical assay for estrogen receptor: relationship to outcome of therapy in patients with advanced breast cancer. Cancer Res., 46, 4241(s)-4243(s).
57. MCCLELLAND RA, FINLAY P, DIXON AR, ROBERTSON JFR, ELLIS IO, BLAMEY RW AND NICHOLSON RI. (1993). Epidermal growth factor receptors and oestrogen receptor expression in breast cancer: Relationship to endocrine sensitivity. Oncol. (Life Sci. Adv.), 12, 143-155.
58. MCGUIRE WL, CARBONNE PP, SEARS ME AND ESCHER GC. (1975). Estrogen receptors in human breast cancer: an overview. In Estrogen Receptors in Human Breast Cancer, McGuire WL, Carbonne PP and Vollmer EP (eds.) pp. 1-7. Raven Press: New York.
59. MCGUIRE WL, ZARA DT, HORWITZ KB AND CHAMNESS GC. (1978). Hormones, receptors and breast cancer. In Proceedings of the Sixth Tenovus Workshop on Tumour Markers, Griffiths K, Neville AM and Pierrepoint CG (eds.) pp. 153-161. Alpha Omega Publishing: Cardiff.
60. MALAFA M, CHAUDHURI B, THOMFORD NR AND CHAUDHURI PK. (1990). Estrogen receptors in ductal carcinoma in situ of breast. Ann. Surg., 56, 436-439.
61. MARGREITER R AND WIEGELE J. (1984). Tamoxifen (Nolvadex) for premenopausal patients with advanced breast cancer. Breast Cancer Res. Treat., 4, 45-48.
62. MARKOPOULOS C, BERGER U, WILSON P, GAZET JC AND COOMBES RC. (1988). Oestrogen receptor content of normal breast cells and breast carcinoma throughout the menstrual cycle. Br. Med. J., 296, 1349-1351.
63. MASON BH, HOLDAWAY IM, MULLINS PR, YEE LH AND KAY RG. (1983). Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Res., 43, 2985-2990.
64. MASTERS JRW, HAWKINS RA, SANGSTER K, HAWKINS W, SMITH II, SHIVAS AA, ROBERTS MM AND FORREST APM. (1978). Oestrogen receptors, cellularity, elastoses and menstrual status in human breast cancer. Eur. J. Cancer, 14, 303-307.
65. MAYNARD PV, BLAMEY RW, ELSTON CW, HAYBITTLE JL AND GRIFFITHS K. (1978). Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Cancer Res., 38, 4292-4295.
66. MOOLGAVAKAR SH, DAY NE AND STEVENS RG. (1980). Two stage model for carcinogenesis: epidemiology of breast cancer in females. J. Natl Cancer Inst., 65, 559-569.
67. MORROW M AND JORDAN VC. (1993). Molecular mechanisms of resistance to Tamoxifen therapy in breast cancer. Arch. Surg., 128, 1187-1191.
68. MULLICK A AND CHAMBON P. (1990). Characterisation of the estrogen receptor in two antioestrogen-resistant cell lines, LY2 and T47D. Cancer Res., 50, 333-338.
69. MURPHY CS, PINK JJ AND JORDAN VC. (1990). Characteristics of a receptor-negative hormone non-responsive clone derived from T47D human breast cancer cell line kept under oestrogen free conditions. Cancer Res., 50, 7285-7292.
70. MURPHY C, SIBBERING M, ELLIS IO, PINDER S, BELL JA, BLAMEY RW AND ROBERTSON JFR Progesterone receptor status in DCIS (submitted).
71. MURRAY PA, GOMM J, RICKETTS D, POWLES T AND COOMBES RC. (1994). The effect of endocrine therapy on the levels of oestrogen and progesterone receptor and transforming growth factor-β1 in metastatic human breast cancer: an immunocytochemical study. Eur. J. Cancer, 2, 1218-1222.
72. MURRAY RML AND PITT P. (1982). Aminoglutethamide in Tamoxifen-resistant patients: The Melbourne experience. Cancer Res., 42, 3437s-3441s.
73. NAMER M, LALAANE C AND BAULIEU E-E. (1980). Increase of progesterone receptor by Tamoxifen as a hormonal challenge test in breast cancer. Cancer Res., 40, 1750-1752.
74. NEWSOME JF, AVIS FP, HAMMOND JE AND SHERWOOD S. (1981). Sampling procedures in estrogen receptor determinations. Ann. Surg.. 193, 549-554.
75. NICHOLSON RI, COLIN P, FRANCIS AB, KESHRA R, FINLAY P, WILLIAMS M, ELSTON CW, BLAMEY RW AND GRIFFITHS K. (1986). Evaluation of an enzyme immunoassay for oestrogen receptors in human breast cancers. Cancer Res., 46, (suppl.) 4299s-4230s.
76. NICHOLSON RI, BOUZUBAR N, WALKER KJ, MCCLELLAND R, DIXON AR, ROBERTSON JFR, ELLIS IO AND BLAMEY RW. (1991). Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation. Eur. J. Cancer, 27, 908-913.
77. NICHOLSON RI, GEE JMW, EATON CL, MANNING DL, MANSEL RE, SHARMA AK, DOUGLAS-JONES A, PRICE-THOMAS M, HOWELL A, DEFRIEND DJ, BUNDRED NJ, ANDERSON E, ROBERTSON JFR, BLAMEY RW, DOWSETT M, BAUM M, WALTON P AND WAKELING AE. (1994). Pure antioestrogens in breast cancer: experimental and clinical observations. In Sex Hormones and Anti-hormones in Endocrine-dependent Pathologies, Motta M and Serio M (eds.) pp. 347-360. Excerpta Medica: Amsterdam.
78. NOGUCHI S, MIYAUDI K, NISHIZAWA Y AND KOYAMA H. (1988). Induction of progesterone receptor with Tamoxifen in human breast cancer with special reference to its behaviour over time. Cancer, 61, 1345-1349.
79. NOMURA Y, TASHIRO H AND SHINOZUKA K. (1985). Changes in steroid hormone receptor content by chemotherapy and or endocrine therapy in advanced breast cancer. Cancer, 55, 546-551.
80. OSBORNE CK. (1993). Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism. J. Steroid. Biochem. Mol. Biol., 47, 83-89.
81. OSBORNE CK, YOCHMOWITZ MG, KNIGHT WA AND MCGUIRE WL. (1980). The value of oestrogen and progesterone receptors in the treatment of breast cancer. Cancer, 46, 2884-2888.
82. OSBORNE CK, CORONADO EB AND ROBINSON JP. (1987). Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur. J. Cancer Clin. Oncol., 23, 188-196.
83. OSBORNE CK, CORONADO EB, ALLRED DC, WIEBE V AND DE GREGORIO M. (1991). Acquired tamoxifen resistance: correlation with reduced tumour levels of tamoxifen and isomerisation of trans-4-hydroxytamoxifen. J. Natl Cancer Inst., 83, 1477-1482.
84. OSBORNE CK, JARMAN M, MACAGUE R, CORONADO EB, DE GREGORIO MW, HILSENBECK SG AND WAKELING AE. (1994). The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumour growth. Cancer Chemother. Pharmacol., 34, 89-95.
85. PAIK S, HARTMANN DP, DICKSON RB AND LIPPMAN ME. (1994). Antiestrogen resistance in ER positive breast cancer cells. Breast Cancer Res. Treat., 31, 301-307.
86. PALLIS L, WILKING N, CEDERMARK B, RUTQUISK LE AND SKOOG L. (1992). Receptors for estrogen and progesterone in breast carcinoma in situ. Anticancer Res., 12, 2113-2115.
87. PARIDAENS R, SYLVESTER RJ, FERAZZI E, LEGROS N, LECLERCQ G AND HEUSON JC. (1980). Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancer. Cancer, 46, 2889-2895.
88. PEETZ ME, NUNLEY DL, MOSELEY HS, KEENAN EJ, DAVENPORT CED AND FLETCHER WS. (1982). Multiple simultaneous and sequential estrogen receptor values in patients with breast cancer. Am. J. Surg., 143, 591-594.
89. POLLER DN, SNEAD DRJ, ROBERTS EC, GALEA M, BELL JA, GILMOUR A, ELSTON CW, BLAMEY RW AND ELLIS IO. (1993). Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the C-erbB2 oncoprotein. Br. J. Cancer, 68, 156-161.
90. ROBERTS AB, FROLIK CA, ANGANO MA AND SPORN MB. (1983). Transforming growth factors from neoplastic and non-neoplastic tissues. Fed. Proc., 42, 2621-2626.
91. ROBERTS MM, RUBENS RD, KING RJB, HAWKINS RA, MILLS RR, HAYWARD JL AND FORREST APM. (1978). Oestrogen receptors and response to endocrine therapy in advanced breast cancer. Br. J. Cancer, 38, 431-437.
92. ROBERTSON JFR, WILLIAMS MR, TODD J, NICHOLSON RI, MORGAN DAL AND BLAMEY RW. (1989). Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur. J. Cancer Clin. Oncol., 25, 469-475.
93. ROBERTSON JFR, ELLIS IO, NICHOLSON RI, ROBINS A, BELL J AND BLAMEY RW. (1991). Cellular effects of tamoxifen in primary breast cancer. Breast Cancer Res. Treat., 20, 117-123.
94. ROBERTSON JFR, BATES K, PEARSON D, BLAMEY RW AND NICHOLSON RI. (1992). Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer. Br. J. Cancer, 65, 727-730.
95. SAINSBURY JRC, FARNDON JR, SHERBET GV AND HARRIS AL. (1985). Epidermal growth factor receptors and oestrogen receptors in human breast cancer. Lancet, 1, 364-366.
96. SAMAAN NA, BUZDAR AV, ALDINGER KA, SCHULTZ PN, YANG K, ROMSDAHL MM AND MARTIN R. (1981). Estrogen receptor - a prognostic factor in breast cancer. Cancer, 47, 554-560.
97. SAWKA CA, PRITCHARD PI, PATERSON AHU, SUTHERLAND DJA, THOMSON DB, SHELLEY WE, MYERS RE, MOBBS BG, MALKIN A AND MEAKIN JW. (1986). Role and mechanism of action of Tamoxifen in premenopausal women. Cancer Res., 46, 3152-3156.
98. SHARMA AK, HORGAN K, DOUGLAS-JONES A, MCCLELLAND R, GEE J AND NICHOLSON RI. (1994). Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer. Br. J. Cancer. 69, 1032-1037.
99. SILFVERSWARD C, SKOOG L, HUMLS S, GUSTAFSSON SA AND NORDENSKOJD B. (1980). Intratumoral variation of cytoplasmic and nuclear estrogen receptor concentrations in human mammary carcinoma Eur. J. Cancer, 16, 59-65.
100. SMITH IE, HARRIS AL, MORGAN M, FORD HT, GAZET J-C, HARMER C, WHITE H, PARSONS CA, VITTARDO A, WALSH G AND MCKINNA JA. (1981). Tamoxifen versus aminoglutethamide in advanced breast cancer: a randomised crossover trial. Br. J. Med., 283, 1432-1434.
101. SOOMRO S, SHOUSHA S AND SINNETT HD. (1992). Oestrogen and progesterone receptors in screen-detected breast carcinoma. An immunohistological study using paraffin sections. Histopathology, 21, 543-547.
102. STRAUS MJ, MORAN RE, MULLER RE AND WAITZ HH. (1982). Estrogen receptor heterogeneity and the relationship between estrogen receptor and the tritiated thymidine labelling index in human breast cancer. Oncology, 39, 197-200.
103. TAYLOR RE, POWLES TJ, HUMPHREYS J, BETHLEHEIM R, DOWSETT M, CASEY AJ, NEVILLE AM AND COOMBES RR. (1982). Effects of endocrine therapy on steroid receptor content of breast cancer. Br. J. Cancer, 45, 80.
104. THORPE SM. (1987). Monoclonal antibody technique for detection of estrogen receptors in human breast cancer. Greater sensitivity and more accurate classification of receptor status than dextrancoated charcoal method. Cancer Res., 47, 6572-6575.
105. TILLEY WD, KEIGHTLEY DD AND CANT EL. (1978). Inter-site variation of estrogen receptors in human breast cancer. Br. J. Cancer, 38, 544-546.
106. TOI M, HAMADA Y, NAKAMURA T, MUKAIDA H, SUEHIRO S, WADA T, TOGE T, NIIMOTO M AND HATTORI T. (1989). Immunocytochemical and biochemical analysis of epidermal growth factor expression in human breast cancer tissues: Relationship to oestrogen receptor and lymphatic invasion. Int. J. Cancer, 43, 220-225.
107. VAN DEN BERG HW, LYNCH M, MARTIN J, NELSON J, DICKSON GR AND CROCKARD AD. (1989). Characterisations of a Tamoxifen-resistant variant of the ZR-75-1 human breast cancer cell line (ZR-95-9a1) and stability of the resistant phenotype. Br. J. Cancer, 59, 522-526.
108. WALKER KJ, BOUZABAR N, ROBERTSON J, ELLIS IO, ELSTON CW, BLAMEY RW, WILSON DW, GFIFFITHS K AND NICHOLSON RI. (1988). Immunocytochemical localisation of estrogen receptor in human breast tissue. Cancer Res., 48, 6517-6522.
109. WALKER KJ, MCCLELLAND RA, CANDLISH W AND NICHOLSON RI. (1992). Heterogeneity of oestrogen receptor expression in normal and malignant breast tissue. Eur. J. Cancer, 28, 34-37.
110. WALT AJG, SINGHAKOWINTA A, BROOKS SC AND CORTEZ A. (1976). The surgical implications of estrophile protein estimations in carcinoma of the breast. Surgery, 80, 506-512.
111. WASEDA N, KATO Y, IMURA H AND KURATA M. (1981). Effects of Tamoxifen on estrogen and progesterone receptors in human breast cancer. Cancer Res., 41, 1984-1988.
112. WILBUR DC AND BARROWS GH. (1993). Estrogen and progesterone receptor and cerbB2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study. Mod. Pathol., 6, 114-120.
113. WILKINSON P, RIBEIRO G, ADAM H AND PATTERSON J. (1980). Clinical pharmacology of Tamoxifen and N-desmethyl Tamoxifen in patients with advanced breast cancer. Cancer Chemother. Pharmacol., 5, 109.
114. WILLIAMS MR, TODD JH, ELLIS IO, DOWLE CS, HAYBITTLE JL, ELSTON CW, NICHOLSON RI, GRIFFITHS K AND BLAMEY RW. (1987). Oestrogen receptors in primary and advanced breast cancer: An eight year review of 704 cases. Br. J. Cancer, 55, 67-73.
115. YANO T, KORKOT E, PINSKI J, SZEPESHAZI IC, MILOVANOVIC S, GROOT K, CLARKE R, COMARU-SCHALLY AM AND SCHALLY AV. (1992). Inhibition of growth of MCF-6 - Mill human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH. Br. Cancer Res. Treat., 21, 35-45.